{"id":"dalbavancin-administration","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dalbavancin works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, preventing proper cell wall formation and leading to bacterial cell death. It has a long half-life (approximately 14 days) allowing for extended dosing intervals. The drug is effective against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and other resistant pathogens.","oneSentence":"Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:35.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bacterial skin and skin structure infections (ABSSSI)"},{"name":"Gram-positive bacterial infections including MRSA"}]},"trialDetails":[{"nctId":"NCT06810583","phase":"PHASE1","title":"A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-05-22","conditions":"Leukemia, Acute Myeloid Leukemia, Lymphoblastic Leukemia in Children","enrollment":29},{"nctId":"NCT06688084","phase":"","title":"Pathogenicity Factors of Staphylococcus Pettenkoferi in Foot Wounds and Osteitis in Diabetic Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2024-01-01","conditions":"Diabetic Foot Ulcer","enrollment":230},{"nctId":"NCT06423898","phase":"PHASE4","title":"Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.","status":"RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2024-10-09","conditions":"Endocarditis, Infective","enrollment":284},{"nctId":"NCT05117398","phase":"PHASE3","title":"Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-23","conditions":"Catheter Bacteremia, Staphylococcus Aureus Infection","enrollment":406},{"nctId":"NCT06899906","phase":"","title":"Efficacy and Safety of Dalbavancin As Suppressive Therapy","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-10-01","conditions":"Efficacy and Safety of Dalbavancin, In Subjects Who Received SAT with DAL, For Acute or Chronic Infections Between July 2019 and December 2024","enrollment":33},{"nctId":"NCT04775953","phase":"PHASE2","title":"DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Staphylococcal Bacteraemia","enrollment":200},{"nctId":"NCT02814916","phase":"PHASE3","title":"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-30","conditions":"Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections","enrollment":199},{"nctId":"NCT06266494","phase":"PHASE4","title":"Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-03-01","conditions":"Frostbite","enrollment":100},{"nctId":"NCT04624451","phase":"","title":"Evaluation of Intravenous Dalbavancin for Peritonitis","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2020-06-01","conditions":"Peritonitis, Peritonitis Bacterial","enrollment":2},{"nctId":"NCT05046860","phase":"NA","title":"Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2022-03-07","conditions":"Osteoarticular Infection","enrollment":43},{"nctId":"NCT04847921","phase":"PHASE2, PHASE3","title":"Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2021-04-30","conditions":"Gram-Positive Bacterial Infections, Gram-Positive Bacteraemia, Substance Use Disorders","enrollment":11},{"nctId":"NCT03426761","phase":"PHASE4","title":"Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections","status":"COMPLETED","sponsor":"Infectious Diseases Physicians, Inc.","startDate":"2018-01-25","conditions":"Bone Infection, Osteomyelitis, Septic Arthritis","enrollment":41},{"nctId":"NCT03982030","phase":"PHASE4","title":"Dalbavancin Outpatient Pilot","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2023-04","conditions":"Gram-Positive Bacterial Infections, Soft Tissue Infections","enrollment":""},{"nctId":"NCT03372941","phase":"PHASE4","title":"Hospital Avoidance Strategies for ABSSSI","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2019-03-04","conditions":"Skin Infection","enrollment":11},{"nctId":"NCT04485676","phase":"","title":"Dalbavancin in Real Clinical Practice in Spain","status":"COMPLETED","sponsor":"Angelini Farmacéutica","startDate":"2020-07-15","conditions":"Skin Diseases, Bacterial, Skin Diseases, Infectious","enrollment":187},{"nctId":"NCT03148756","phase":"PHASE2","title":"Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis","status":"TERMINATED","sponsor":"AbbVie","startDate":"2017-05-12","conditions":"Endocarditis, Bacteremia","enrollment":2},{"nctId":"NCT03726216","phase":"","title":"Xydalba Utilization Registry in France","status":"COMPLETED","sponsor":"Correvio International Sarl","startDate":"2018-09-06","conditions":"Bacterial Infections","enrollment":151},{"nctId":"NCT02940730","phase":"PHASE4","title":"Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-05-01","conditions":"Infectious Peritonitis","enrollment":10},{"nctId":"NCT03696901","phase":"","title":"Xydalba Utilization Registry in Germany","status":"TERMINATED","sponsor":"Correvio International Sarl","startDate":"2018-11-21","conditions":"Bacterial Infections","enrollment":16},{"nctId":"NCT03941951","phase":"NA","title":"Study to Optimize the Use of New Antibiotics","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2019-07-09","conditions":"Bacterial Infections, Fungal Infection","enrollment":900},{"nctId":"NCT02961764","phase":"PHASE4","title":"Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-11-29","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":313},{"nctId":"NCT03233438","phase":"PHASE4","title":"Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","status":"COMPLETED","sponsor":"Allergan","startDate":"2017-07-24","conditions":"Bacterial Infections, Acute Bacterial Skin and Skin Structure Infection","enrollment":91},{"nctId":"NCT02685033","phase":"PHASE2","title":"Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2016-03-15","conditions":"Osteomyelitis","enrollment":80},{"nctId":"NCT02127970","phase":"PHASE3","title":"Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2014-04-18","conditions":"Abscess, Wound Infection, Surgical Site Infection","enrollment":698},{"nctId":"NCT03091439","phase":"PHASE2","title":"Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis","status":"TERMINATED","sponsor":"Allergan","startDate":"2017-05-15","conditions":"Osteomyelitis","enrollment":1},{"nctId":"NCT02344511","phase":"PHASE3","title":"Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis","status":"WITHDRAWN","sponsor":"Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)","startDate":"2016-03","conditions":"Osteomyelitis","enrollment":""},{"nctId":"NCT02269644","phase":"PHASE3","title":"A P3 Comparator Trial in Community Acquired Bacterial Pneumonia","status":"WITHDRAWN","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2015-11","conditions":"Community Acquired Pneumonia","enrollment":""},{"nctId":"NCT01946568","phase":"PHASE1","title":"A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2013-06","conditions":"Bacterial Infections.","enrollment":36},{"nctId":"NCT01431339","phase":"PHASE3","title":"Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2011-07","conditions":"Abscess, Wound Infection, Surgical Site Infection","enrollment":739},{"nctId":"NCT01339091","phase":"PHASE3","title":"Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2011-03","conditions":"Abscess, Wound Infection, Surgical Site Infection","enrollment":573},{"nctId":"NCT00678106","phase":"PHASE1","title":"Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Bacterial Infections","enrollment":10},{"nctId":"NCT00057369","phase":"PHASE2","title":"Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections","status":"UNKNOWN","sponsor":"Vicuron Pharmaceuticals","startDate":"2001-02","conditions":"Bacteremia","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xydalba® administration"],"phase":"phase_3","status":"active","brandName":"Dalbavancin administration","genericName":"Dalbavancin administration","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors. Used for Acute bacterial skin and skin structure infections (ABSSSI), Gram-positive bacterial infections including MRSA.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}